Strength of Wisconsin Biohealth

Digital Health:

Where digital technology meets health solutions. Digital health is empowering patients and healthcare systems to provide personalized care, improve quality, and reduce costs. Digital health is Wisconsin’s newest and fastest growing sector.

Medical Device & Diagnostics:

The medical device and diagnostics industry continues to grow and thrive in Wisconsin, with medical device companies ranging from start-ups to corporate powerhouses choosing to call Wisconsin home.

Health Research Institutes:

Wisconsin boasts some of the nations top research institutes. Wisconsin research institutes received $407 million in NIH funding in 2015 with over 927 NIH grants being awarded.

Biotech & Biopharma:

From therapeutic and drug development to translational and integrated science, Wisconsin has it all. Accounting for one of the states’s largest economic drivers, biotech and biopharma continue to flourish in Wisconsin.

Wisconsin: A National Hub for Biomanufacturing

Top Talent. Top Resources. Top Industry.

Innovation. Right here, in Wisconsin.

The FDA has designated StrataGraft, a Stratatech-developed sheet of living tissue made from human cells that form into skin, as a Regenerative Medicine Advanced Therapy (RMAT), the company said. Drugs that treat rare diseases or life-threatening conditions can be placed on a faster regulatory pathway. RMAT creates that faster pathway for regenerative medicine products, including cell therapies and tissue-based products like StrataGraft. The designation allows companies to speak with the FDA earlier and more frequently during the regulatory process. RMAT doesn’t guarantee approval, but if all goes well, it could lead to a quicker FDA decision on the product. Read more here. 

The UW School of Medicine and Public Health, Marshfield Clinic Research Institute and Medical College of Wisconsin have collectively been awarded $5.4 million from the National Institutes of Health to enroll patients in a nationwide precision medicine initiative.

The institutions will partner with the Blood Center of Wisconsin and some of Wisconsin’s federally qualified health centers to recruit participants in the NIH’s All of Us Research Program, which aims to gather data from more than 1 million Americans. Read more here. 

The University of Wisconsin-Madison’s American Family Children’s Hospital will be one of 20 sites to offer one of the most promising and expensive new cancer drugs, one that will come with what amounts to a limited warranty.

UW took part in the clinical trial of the drug Kymriah, which just won approval as a type of gene therapy that harvests a person’s immune cells. The drug treats a rare form of cancer known as acute lymphoblastic leukemia in patients under age 25 who have relapsed or not responded to other treatment. Read more here. 

RPRD (Right Patient Right Drug) Diagnostics, a privately-held, Wisconsin-based precision medicine company, today announced a collaboration with St. Jude Children’s Research Hospital.  RPRD Diagnostics will perform preemptive, comprehensive clinical pharmacogenetics testing for St. Jude’s PG4KDS program.

RPRD (Right Patient Right Drug) Diagnostics, a privately-held, Wisconsin-based precision medicine company, today announced a collaboration with St. Jude Children’s Research Hospital.  RPRD Diagnostics will perform preemptive, comprehensive clinical pharmacogenetics testing for St. Jude’s PG4KDS program.  Read more here.

 

Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), today announces the initiation of a collaboration with Avicenna Oncology GmbH, a leading precision medicine company based in Basel, Switzerland. The collaboration will focus on the development of new phospholipid drug conjugates (PDCs) combining Cellectar’s patented phospholipid ether delivery platform with Avicenna’s novel cytotoxic payloads (potent anti-cancer small molecules).

“We believe the combination of our targeted PDC delivery with Avicenna’s proprietary payloads has tremendous potential for the development of selective therapeutics for patients suffering with cancer,” said Jim Caruso, president and CEO of Cellectar Biosciences.  “This collaboration further validates the utility of our PDC delivery platform to provide targeted treatment of various resistant cancers, expands and accelerates our conjugate program research and potentially increases our novel, small molecule PDC pipeline.” Read more here. 

QUALITY OF LIFE

biohealth3

Welcome home: Wisconsin is home to endless outdoor activities throughout all seasons, growing tech & health industries, and a top-tier university system making our home the 8th state in the 2016 Quality of Life list by Forbes.

COLLABORATION

biohealth2

When industries and instituitions converge and great minds connect, big things happen. Read about collaboration success stories that started right here in Wisconsin and learn how to start your own collaboration story.

TALENT

biohealth1

Wisconsin boasts both a world-class university system and top-tier talent.  Madison ranks 1st for STEM college graduates. Search our career center for opportunites or find your future hire here:

2015 Wisconsin Bioscience Economic Development Report: Energizing Wisconsin's Economy

READY TO JOIN THE MOVEMENT?

Contact our team member Kate at krodgers@bioforward.org to learn how to get involved!

Sign Up For Our NewsletterView WI Biohealth eventsFollow Us on Social